As part of a joint effort to advance Nigeria’s pharmaceutical manufacturing capacity and strengthen local health systems, the Federal Government, in partnership with the European Union (EU) and France, has signed a strategic partnership agreement under the Global Gateway’s Manufacturing and Access to Vaccines, Medicines and Health Technologies (MAV+) Initiative.
The project, named Quality Uplift for Advancing Local Industry in Medicine Standards (Qualimeds Nigeria), aims to bolster Nigeria’s pharmaceutical ecosystem by expanding the local production of quality-assured medicines, improving access to essential health technologies, and promoting research-based innovation.
Additionally, the project will reinforce the National Institute for Pharmaceutical Research and Development (NIPRD) as a regional reference centre for critical activities such as bioequivalence, stability studies, and quality control, fostering regional collaboration with Rwanda and Senegal.
With a total investment of €10.2 million (including €10 million from the EU and €200,000 co-financing from the French Ministry for Europe and Foreign Affairs), the 44-month project (2025-2028) will be implemented in collaboration with the Federal Ministry of Health and Social Welfare, NIPRD, and other local partners.
